📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. The pediatric development plan — the US Pediatric Study Plan (PSP) and the EU Paediatric Investigation Plan (PIP).

Why it exists. Both the FDA and EMA require sponsors to plan (or justify deferral/waiver of) studies in children early in development. The plan states what pediatric studies will be done, or why they are not needed, for GLPI-103.

How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.

Format & governing standard. FDA PREA/PSP; EU Paediatric Regulation (PIP)

Pediatric Plan (US PSP / EU PIP) — GLPI-103

Field	Value
Document ID	PED-001
Version	1.0
Standard	FDA PREA/PSP; EU Paediatric Regulation (PIP)
Confidentiality	Confidential — portfolio use

Combined summary of the US Pediatric Study Plan (PSP) and EU Paediatric Investigation Plan (PIP) required for the marketing application. [MOCK].

Change History

Version	Date	Author	Summary
1.0	2026-06-29	Regulatory	Initial pediatric plan

1. Condition & Relevance

Type 2 diabetes mellitus occurs in adolescents; a pediatric development plan is required (or a waiver/deferral justified) for the new active substance.

2. Proposed Approach

Deferral of pediatric studies until adult efficacy/safety is established (pivotal GLPI103-301 complete).
Planned adolescent (10–<18 y) study of efficacy/safety/PK with appropriate formulation; pediatric PK modeling and extrapolation where scientifically justified.
Waiver proposed for children below the age where T2DM is not relevant.

3. Regulatory Interactions

PSP agreed with FDA (PREA); PIP agreed with the EMA Paediatric Committee (PDCO), including key binding measures and timelines. Updates submitted as the program matures.